In a case that underscores the high-stakes intersection of academic institution IP rights and medical device commercialization, the University of South Florida Board of Trustees and Stryker Corporation jointly stipulated to dismiss their patent infringement dispute with prejudice on February 29, 2024, just 175 days after filing. The case, docketed as 8:23-cv-02013 before the Florida Middle District Court, centered on two issued U.S. patents — US9646423B1 and US9547940B1 — alleged to cover technology embodied in Stryker’s TGS® ENT navigation system. Each party agreed to bear its own legal fees and costs, signaling a negotiated exit rather than a litigation defeat.

For patent counsel and in-house IP professionals in the medical device sector, this rapid resolution carries significant strategic weight. When a university technology transfer office asserts foundational navigation patents against a market leader like Stryker — represented by King & Spalding LLP — a swift, prejudicial dismissal almost invariably reflects a licensing arrangement or settlement. R&D teams developing surgical navigation and ENT imaging technology must now assess whether these patents remain licensing tools or whether any cross-licensing terms affect freedom-to-operate in adjacent product spaces.

Case Overview

The Parties

The Patents at Issue

US9646423B1 and US9547940B1 both relate to surgical navigation technology used in ENT (ear, nose, and throat) procedures, specifically systems that track the position of surgical instruments in real time relative to pre-operative or intraoperative imaging data. The patents’ claims likely encompass methods and apparatus for registering three-dimensional anatomical models to a patient’s physical anatomy during surgery and displaying instrument position to the surgeon. These technologies are foundational to image-guided ENT surgery platforms, enabling safer and more precise navigation through complex sinus and skull-base anatomy.

• • US9646423B1
• • US9547940B1

Legal Representation

Plaintiff Counsel: Fee & Jeffries PA (lead: Kathleen M. Wade)
Defendant Counsel: King & Spalding LLP (lead: Abby L. Parsons)

Litigation Timeline & Procedural History

The case was filed on September 7, 2023, in the Middle District of Florida — a venue that, while not traditionally considered a patent rocket docket, offers geographic relevance given USF’s Tampa-area presence. Filing at the first-instance district court level follows the standard federal patent infringement litigation pathway under 35 U.S.C. § 271, placing the dispute before a single district judge with the potential for full Markman claim construction proceedings, summary judgment motions, and jury trial if not resolved earlier.

The case closed on February 29, 2024, after only 175 days — a notably brief duration for patent litigation involving complex medical device technology. This timeline strongly suggests the parties reached a negotiated resolution, likely a licensing agreement or cross-licensing arrangement, very early in the discovery or pre-Markman phase. The dismissal was executed pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii), a stipulated dismissal mechanism requiring no court order, confirming that both parties moved swiftly to conclude the matter before significant judicial resources were expended. The ‘with prejudice’ designation ensures USF cannot re-file the same infringement claims against Stryker on these patents.

The Verdict & Legal Analysis

Outcome

The action was terminated by a stipulated dismissal with prejudice under FRCP 41(a)(1)(A)(ii), with each party bearing its own attorneys’ fees and costs. No damages award was issued, no injunctive relief was granted or denied, and no claim construction or invalidity determination was reached by the court. The mutual fee-bearing arrangement eliminates any inference of a clear litigation winner and is consistent with the terms typically accompanying a confidential licensing settlement.

Verdict Cause Analysis

The verdict cause — an infringement action resolved by stipulated dismissal — reflects a specific procedural and strategic dynamic worth unpacking for IP practitioners

• A stipulated dismissal with prejudice under FRCP 41(a)(1)(A)(ii) requires the consent of all parties and operates as a final adjudication on the merits for res judicata purposes, permanently barring USF from re-asserting these specific patents against Stryker.
• The mutual cost-bearing provision is a standard hallmark of a confidential settlement or licensing resolution, as prevailing parties in litigation typically seek cost-shifting under 35 U.S.C. § 285 or Rule 54(d).
• The 175-day resolution timeline suggests the parties may have engaged in pre-suit licensing discussions that continued into the litigation phase, with the complaint filing serving as a negotiating catalyst rather than a commitment to full-scale trial.
• No claim construction order, summary judgment ruling, or invalidity finding was entered, meaning the patents US9646423B1 and US9547940B1 remain presumptively valid and enforceable against third parties outside this settlement.

Legal Significance

1. 1. Because the case resolved without a Markman ruling or merits adjudication, the claim scope of US9646423B1 and US9547940B1 remains judicially undefined, which preserves USF’s flexibility to assert broader or narrower claim interpretations in future enforcement actions against other defendants in the ENT navigation market.
2. 2. The dismissal with prejudice creates a jurisdictional bar only as between USF and Stryker — third-party competitors in the ENT surgical navigation space, such as Medtronic or Karl Storz, remain fully exposed to infringement assertions under these same patents without the benefit of any claim construction or invalidity precedent from this case.
3. 3. University patent assertion cases settled at this early stage often result in ongoing royalty arrangements tied to product revenue, meaning the patents may continue to shape Stryker’s product cost structure and pricing in the TGS® product line even after the litigation concluded.

Strategic Takeaways

For Patent Attorneys:

• When representing defendants against university patent holders in early-stage litigation, prioritize a rapid validity assessment of the asserted patents — university patents often have narrower prosecution histories and face stronger obviousness challenges given the academic publication records of the named inventors.
• The FRCP 41(a)(1)(A)(ii) mechanism is a clean exit tool in settled patent disputes; ensure settlement agreements expressly address the scope of the dismissal’s preclusive effect on related patents in the same family or continuation applications.
• Monitor USF’s remaining patent portfolio in the surgical navigation space for continuation patents or continuation-in-part applications that may not be captured by the with-prejudice bar, as university technology transfer offices frequently file continuation chains on commercially valuable technology.
• The absence of a fee-shifting motion by either party is instructive — in cases where settlement is likely, refraining from early aggressive motion practice (such as exceptional case motions) preserves goodwill and negotiating flexibility.

For IP Professionals:

• In-house IP teams at medical device companies should implement a systematic watch on university patent portfolios in their core technology areas, particularly where universities hold foundational navigation or imaging patents that predate commercial product launches — USF’s assertion against Stryker’s TGS® system illustrates how academic IP can intersect with established commercial product lines.
• A rapid, confidential settlement with a prejudicial dismissal may resolve immediate exposure but can signal to other university IP holders that the defendant has licensing capacity; monitor for follow-on assertions from other academic institutions holding adjacent ENT navigation patents.

For R&D Teams:

• R&D teams developing ENT surgical navigation systems should conduct FTO analysis against US9646423B1 and US9547940B1 before product launch, as these patents remain valid and enforceable against all parties outside the Stryker settlement and cover core image-guidance and instrument-tracking methodologies.
• Consider design-around strategies that leverage post-grant proceedings — IPR petitions at the USPTO against USF’s navigation patents could be a cost-effective tool to neutralize these assets before a product reaches commercialization, particularly given the academic publication landscape that may supply prior art.